{"id":936587,"date":"2026-02-12T08:58:01","date_gmt":"2026-02-12T13:58:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/"},"modified":"2026-02-12T08:58:01","modified_gmt":"2026-02-12T13:58:01","slug":"aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/","title":{"rendered":"AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Live video webcast with Tom\u00a0Equels, Chief Executive Officer of AIM\u00a0ImmunoTech, on\u00a0Thursday,\u00a0February\u00a019th at\u00a04:00 PM ET<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Event to focus on lead program, Ampligen, for treatment of pancreatic cancer<\/em>\n      <\/p>\n<p align=\"justify\">OCALA, Fla., Feb.  12, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ya9zkA_h_a3i3TYJ3TX9gKz3ZcedMVo0xexfVkCjxxnUZSNLZMr6jZ2lqRleAQT7F-hpuuUJ62GV-BsUNZ42-UWAy5InQV79u0-j_XnTsFs=\" rel=\"nofollow\" target=\"_blank\"><strong>AIM ImmunoTech Inc.<\/strong><\/a><strong> (NYSE American: AIM)\u00a0<\/strong>(\u201cAIM\u201d or the \u201cCompany\u201d) today announced that <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PZSit7Univl3FdZV3O3bIogjChbCctnKbxEBHFr8UUWrpvleQ8TxFXuEa-9QTaByAPDxFFmEjCEK_OGWC00zsD8tU-cPA8H2sBF9UP674Spi_j9NT4uXUjbE87X9rwQlEZpCrlFaQ6i88djOkXUTb8LiFskIAj7hvS7yXi2JTS0=\" rel=\"nofollow\" target=\"_blank\">Thomas K. Equels, MS JD, Chief Executive Officer<\/a> of AIM, will\u00a0participate\u00a0in a\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m3F-CsCnVozT-g6X1tpoZbYJqVPHJPEIi0GTBdGKyUcz8GrvgmP3UaD6afpzLqRmMyCvsJSld5xQf1NIvf1XDcZ9lndwnKDK3IGQ4t4MVvlmVESFmmn2Y2Y6qcKZJ8iLs23W5L1fpXEjOs8oYcWs10bvQGgJXfkqvDvBCN-OdDColnXSvul5NM5UWVm45Bnr\" rel=\"nofollow\" target=\"_blank\">Virtual Investor Closing Bell Event<\/a>\u00a0on\u00a0Thursday, February 19,\u00a02026,\u00a0at 4:00 PM ET.<\/p>\n<p align=\"justify\">Equels will focus on AIM\u2019s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L_oha2o-gMHzAGWonPpo-SSvxDVCCt6qDxDtNLbEGVmOfIeELChcDJJWmc79Cmu4QEanQgbxkE03HpkYgMu2SlxX2bpH3ApyyXG9yK_U1lJ-0878OHB4AosH_vXIBiFC\" rel=\"nofollow\" target=\"_blank\">DURIPANC clinical trial<\/a>\u00a0in collaboration with AstraZeneca combining Ampligen and AstraZeneca\u2019s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer.<\/p>\n<p align=\"justify\">A\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cTU1X8EXHDhl05uBysdajsQ9C_GCQKRtA3zZnCCrPVavABB64Y0GirIlKPW1bHtQdTeO7CInfWEu5lBEr5r4Fhtcg0yKEIe8FeKsTBIDokbgerpDyRgn5gw96vxOaxzSgI9IQQMpQwd5-sdh1yz3IZ9QAGqazciz7mvkrvn599o=\" rel=\"nofollow\" target=\"_blank\">live video webcast<\/a>\u00a0of the\u00a0presentation\u00a0will be available on the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0aQuRwULTlWmKGmnyi4lW64zQ2ndgBXpzif1R4MR-zIPtQxorm4ELEfLbtNthFH_1fTVvpKsVa6Z_CFFN6LBcQ==\" rel=\"nofollow\" target=\"_blank\">Events<\/a>\u00a0page of the Company\u2019s website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2A2uLJ79Scknrbg_LIAsCLTTOBZf99ZYENeU-FJ34Qi0V0b3MERbvVBHL1X0nOAwVVXijOkJHeR6pp5EKQq7hw==\" rel=\"nofollow\" target=\"_blank\">aimimmuno.com<\/a>). A webcast replay will become\u00a0available\u00a0two hours following the live presentation and will be accessible for\u00a090 days.<\/p>\n<p>\n        <strong>About AIM ImmunoTech Inc.<\/strong><br \/>\n        \n      <\/p>\n<p align=\"justify\">AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen<sup>\u00ae<\/sup> (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.<\/p>\n<p>For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2A2uLJ79Scknrbg_LIAsCJ7YqfXBusPj5nzYKZY5ngsN8DPRUXuWn3W7BgmCrNTFl0Tr_F9k5o4Lu7fxyMWVVw==\" rel=\"nofollow\" target=\"_blank\">aimimmuno.com<\/a>\u00a0and connect with the Company on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hXf2yktOZGkiigLcXMMRlcmdgpQzhP0GBzt_Pp5NHR2AMKGAoEuzH0N2TwHJdpAt_XNdfgymUUFGZxo5_Gi5zQ==\" rel=\"nofollow\" target=\"_blank\">X<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l30gnKVy8WSqka4mgn5hDHS4IdL6zVDLv50G2zLAJzTh-DMkT0-XgCXpmEHgMKig6HRxHCNL1IQhJDicnAI03vnnVN38dlcLNJarAO7efI50-WuEA4zhHq30P4ZQvhBz5IFmtc31V5DVveuXuswcXA==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s8nogTLawA3Syth4v4oFP3eSVfWt_dGObQY_MCAtyhn4PliDsjz8PSEf_GgsalcSnszjVQ997-lvTixtTTMhNOXYfqN0oM7s8jDw9RR658o=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzIzMyM3NDIyMDQyIzIwMjMxNjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/N2I3N2NlOWUtZGY1NS00ZjU5LWIxMGYtODc2MDBjNzkzYTU4LTEwMzQ3MzUtMjAyNi0wMi0xMi1lbg==\/tiny\/AIM-ImmunoTech-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Contact:\r\n\r\nJTC Team, LLC\r\nJenene Thomas\r\n908.824.0775\r\nAIM@jtcir.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Live video webcast with Tom\u00a0Equels, Chief Executive Officer of AIM\u00a0ImmunoTech, on\u00a0Thursday,\u00a0February\u00a019th at\u00a04:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) &#8212; AIM ImmunoTech Inc. (NYSE American: AIM)\u00a0(\u201cAIM\u201d or the \u201cCompany\u201d) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will\u00a0participate\u00a0in a\u00a0Virtual Investor Closing Bell Event\u00a0on\u00a0Thursday, February 19,\u00a02026,\u00a0at 4:00 PM ET. Equels will focus on AIM\u2019s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing\u00a0DURIPANC clinical trial\u00a0in collaboration with AstraZeneca combining Ampligen and AstraZeneca\u2019s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer. A\u00a0live video webcast\u00a0of the\u00a0presentation\u00a0will be available on the\u00a0Events\u00a0page of the Company\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-936587","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Live video webcast with Tom\u00a0Equels, Chief Executive Officer of AIM\u00a0ImmunoTech, on\u00a0Thursday,\u00a0February\u00a019th at\u00a04:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) &#8212; AIM ImmunoTech Inc. (NYSE American: AIM)\u00a0(\u201cAIM\u201d or the \u201cCompany\u201d) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will\u00a0participate\u00a0in a\u00a0Virtual Investor Closing Bell Event\u00a0on\u00a0Thursday, February 19,\u00a02026,\u00a0at 4:00 PM ET. Equels will focus on AIM\u2019s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing\u00a0DURIPANC clinical trial\u00a0in collaboration with AstraZeneca combining Ampligen and AstraZeneca\u2019s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer. A\u00a0live video webcast\u00a0of the\u00a0presentation\u00a0will be available on the\u00a0Events\u00a0page of the Company\u2019s &hellip; Continue reading &quot;AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-12T13:58:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzIzMyM3NDIyMDQyIzIwMjMxNjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event\",\"datePublished\":\"2026-02-12T13:58:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\\\/\"},\"wordCount\":243,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MzIzMyM3NDIyMDQyIzIwMjMxNjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\\\/\",\"name\":\"AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MzIzMyM3NDIyMDQyIzIwMjMxNjQ=\",\"datePublished\":\"2026-02-12T13:58:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MzIzMyM3NDIyMDQyIzIwMjMxNjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MzIzMyM3NDIyMDQyIzIwMjMxNjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/","og_locale":"en_US","og_type":"article","og_title":"AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event - Market Newsdesk","og_description":"Live video webcast with Tom\u00a0Equels, Chief Executive Officer of AIM\u00a0ImmunoTech, on\u00a0Thursday,\u00a0February\u00a019th at\u00a04:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) &#8212; AIM ImmunoTech Inc. (NYSE American: AIM)\u00a0(\u201cAIM\u201d or the \u201cCompany\u201d) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will\u00a0participate\u00a0in a\u00a0Virtual Investor Closing Bell Event\u00a0on\u00a0Thursday, February 19,\u00a02026,\u00a0at 4:00 PM ET. Equels will focus on AIM\u2019s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing\u00a0DURIPANC clinical trial\u00a0in collaboration with AstraZeneca combining Ampligen and AstraZeneca\u2019s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer. A\u00a0live video webcast\u00a0of the\u00a0presentation\u00a0will be available on the\u00a0Events\u00a0page of the Company\u2019s &hellip; Continue reading \"AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-12T13:58:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzIzMyM3NDIyMDQyIzIwMjMxNjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event","datePublished":"2026-02-12T13:58:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/"},"wordCount":243,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzIzMyM3NDIyMDQyIzIwMjMxNjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/","name":"AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzIzMyM3NDIyMDQyIzIwMjMxNjQ=","datePublished":"2026-02-12T13:58:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzIzMyM3NDIyMDQyIzIwMjMxNjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzIzMyM3NDIyMDQyIzIwMjMxNjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AIM ImmunoTech to Participate in Live Virtual Investor\u00a0Closing Bell Event"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/936587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=936587"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/936587\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=936587"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=936587"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=936587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}